The estimated Net Worth of Marsha Alpert Chandler is at least $2.27 Mille dollars as of 19 October 2016. Marsha Chandler owns over 4,545 units of Biocept Inc stock worth over $2,267 and over the last 11 years he sold BIOC stock worth over $0. In addition, he makes $0 as Independent Director at Biocept Inc.
Marsha has made over 2 trades of the Biocept Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 4,545 units of BIOC stock worth $5,000 on 19 October 2016.
The largest trade he's ever made was buying 4,545 units of Biocept Inc stock on 19 October 2016 worth over $5,000. On average, Marsha trades about 545 units every 51 days since 2014. As of 19 October 2016 he still owns at least 5,212 units of Biocept Inc stock.
You can see the complete history of Marsha Chandler stock trades at the bottom of the page.
Dr. Marsha Alpert Chandler Ph.D serves as Independent Director of the Company. Dr. Chandler is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego (UCSD). She is also currently Advisor to the Jacobs School of Engineering at UCSD as well as Advisor to the Lyndon B. Johnson School of Public Affairs at The University of Texas at Austin. She served as the Executive Vice-President/Chief Operating Officer of the Salk Institute for Biological Studies from 2007 to 2015, where she managed approximately 1,000 scientific and administrative personnel and oversaw all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she was the Senior Vice Chancellor for Academic Affairs at UCSD, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance. She was the Acting Chancellor from 2003-04 and holds an appointment as Professor of Political Science in the Graduate School of International Relations and Pacific Studies at UCSD. Dr. Chandler is a Fellow of the Royal Society of Canada, the highest academic honor bestowed in that country. She received her Ph.D. from The University of North Carolina at Chapel Hill. In 2004, she completed the Advanced Management Program at Harvard Business School. We selected Dr. Chandler to serve on our board of directors due to her experience in organizational management and her stature in the life sciences community. Dr. Chandler also serves as chair of our nominating and corporate governance committee and as a member of our science, technology and clinical affairs committee.
Marsha Chandler is 75, he's been the Independent Director of Biocept Inc since 2013. There are 1 older and 17 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
Marsha's mailing address filed with the SEC is C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff e David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: